Singapore: +65-85097465 | India: +91-40-42023318
  U.S / Canada Toll Free: +1-866-259-4781
  Zimbabwe: +263-735539685, 773876488

          

Clinical Trial News

Anti-obesity treatment in animal models developed

Researchers from the Spanish National Cancer Research Centre (CNIO) have shown that partial pharmacological inhibition of the PI3K enzyme in obese mice and monkeys reduces body weight and...

Preventative trial in arthritis to bring hope for millions, UK

A pioneering drug to be tested could bring hope to the millions of Britons who are likely to one day suffer from arthritis.

New data supporting Arno Therapeutics' HDAC inhibitor AR-42 published

Arno Therapeutics, Inc., a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics, has announced that data from a preclinical study demonstrate its...

Alzheimer's disease: Anavex presents positive results for both ANAVEX 2-73 and ANAVEX 3-71

Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's and other central nervous system (CNS) diseases, pain and various types of...

Prostate cancer: Astellas announces new enzalutamide data

Astellas Pharma Europe Ltd. has announced new data from the Phase 2 TERRAIN trial of enzalutamide compared to bicalutamide in metastatic castration-resistant prostate cancer (CRPC), as well as an...

Boehringer Ingelheim's investigational biologic cleared skin better than ustekinumab in head-to-head Phase II psoriasis study

For the first time, Boehringer Ingelheim announced Phase II data from its investigational compound BI 655066*.

Results of Pfizer's community‐acquired pneumonia immunization trial in adults (CAPiTA) published

Findings from the Community‐Acquired Pneumonia Immunization Trial in Adults (CAPiTA), published in The New England Journal of Medicine, demonstrate that Prevenar 13®(pneumococcal...

Respiratory diseases: Interim results from new RPL554 trial demonstrates excellent drug tolerability even at highest dose

Verona Pharma plc, the drug development company focused on first-in-class medicines to treat respiratory diseases, has announced encouraging interim results from the first part of a 120 subject...



James Lind Institute Newsletter
James Lind Institute Linkedin
James Lind Institute RSS
James Lind Institute Email Update
James Lind Institute Blog
James Lind Institute Facebook